Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Gross Profit (2016 - 2025)

Historic Gross Profit for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $143.8 million.

  • Myriad Genetics' Gross Profit fell 400.53% to $143.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $580.7 million, marking a year-over-year increase of 1242.98%. This contributed to the annual value of $585.4 million for FY2024, which is 1323.02% up from last year.
  • Myriad Genetics' Gross Profit amounted to $143.8 million in Q3 2025, which was down 400.53% from $151.8 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Gross Profit high stood at $151.8 million for Q2 2025, and its period low was $59.1 million during Q4 2022.
  • Moreover, its 5-year median value for Gross Profit was $129.6 million (2022), whereas its average is $126.1 million.
  • In the last 5 years, Myriad Genetics' Gross Profit skyrocketed by 13180.33% in 2021 and then crashed by 4860.87% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Gross Profit stood at $115.0 million in 2021, then plummeted by 48.61% to $59.1 million in 2022, then surged by 38.75% to $82.0 million in 2023, then skyrocketed by 84.02% to $150.9 million in 2024, then fell by 4.71% to $143.8 million in 2025.
  • Its Gross Profit stands at $143.8 million for Q3 2025, versus $151.8 million for Q2 2025 and $134.2 million for Q1 2025.